MajorAntiretroviral, HIV protease inhibitor×Triazole derivatives, systemic antifungals
Updated · Methodology
Mechanism
CYP2C19, CYP2C9 and CYP3A4 metabolise voriconazole, and voriconazole inhibits these enzymes (voriconazole summary of product characteristics, SmPC, European Medicines Agency, EMA, section 4.5). Ritonavir, used to boost atazanavir, is itself a strong inducer of cytochrome P450 enzymes. Low-dose ritonavir (100 mg twice daily) lowered the voriconazole area under the concentration–time curve (AUC) by 39% (voriconazole SmPC, EMA, section 4.5). With atazanavir 300 mg plus ritonavir 100 mg once daily, the AUC of voriconazole 200 mg fell by 33% and that of atazanavir by 12% in people with at least one functional CYP2C19 allele. In people without a functional allele, the AUC of voriconazole 50 mg rose by 561%, and that of atazanavir fell by 20% (atazanavir SmPC, EMA, section 4.5). Levels of both drugs are therefore expected to fall in most patients. In the small number of people without a functional allele, voriconazole levels are expected to rise markedly (atazanavir SmPC, EMA, section 4.4). There are no studies with unboosted atazanavir or with atazanavir plus cobicistat. Voriconazole may affect atazanavir levels, and CYP3A inhibitors, voriconazole among them, may raise atazanavir and cobicistat levels (atazanavir and atazanavir/cobicistat SmPCs, EMA, section 4.5).
Symptoms
When levels fall, voriconazole and atazanavir may lose efficacy: the fungal infection responds less well, and treatment for human immunodeficiency virus (HIV) may lose its virological response (atazanavir summary of product characteristics, SmPC, European Medicines Agency, EMA, section 4.5; Reyataz prescribing information, US Food and Drug Administration, FDA, section 7). In people without a functional CYP2C19 allele, voriconazole adverse reactions are expected as its levels rise. The most common are visual disturbances, fever, rash, vomiting, nausea, diarrhoea, headache, peripheral oedema, abnormal liver function tests, respiratory distress and abdominal pain (atazanavir and voriconazole SmPCs, EMA, sections 4.5 and 4.8). Voriconazole is associated with QTc prolongation and serious liver reactions. In people with risk factors, torsade de pointes has rarely occurred with voriconazole (voriconazole SmPC, EMA, section 4.4). Atazanavir prolongs the PR interval in a dose-related way (atazanavir SmPC, EMA, section 4.4).
Management
Voriconazole with atazanavir plus ritonavir is not recommended unless an assessment of the benefit and risk for the individual patient justifies voriconazole (atazanavir summary of product characteristics, SmPC, European Medicines Agency, EMA, sections 4.4 and 4.5; Reyataz prescribing information, US Food and Drug Administration, FDA, section 7). The voriconazole SmPC advises avoiding low-dose ritonavir (100 mg twice daily) with voriconazole, with the same benefit-risk proviso (EMA, sections 4.4 and 4.5). With atazanavir plus cobicistat, voriconazole is also not given unless the benefit-risk assessment justifies it. Clinical monitoring may be needed after voriconazole is started (atazanavir/cobicistat SmPC, EMA, sections 4.4 and 4.5). If voriconazole is needed, the CYP2C19 genotype is determined where possible. With at least one functional allele, patients are closely monitored for loss of efficacy of voriconazole (clinical signs) and of atazanavir (virological response). Without a functional allele, they are closely monitored, clinically and with laboratory tests, for voriconazole adverse reactions. If genotyping is not possible, safety and efficacy are fully monitored (atazanavir SmPC, EMA, section 4.5). There are no data with atazanavir without ritonavir, but voriconazole may affect atazanavir levels (atazanavir SmPC, EMA, section 4.5, and FDA, section 7). With other human immunodeficiency virus (HIV) protease inhibitors, the voriconazole SmPC calls for close monitoring for toxicity and lack of efficacy, and a dose adjustment may be needed (EMA, section 4.5). High-dose ritonavir (400 mg twice daily or more) with voriconazole is contraindicated (voriconazole SmPC, EMA, section 4.3). In atazanavir regimens, however, ritonavir is given as 100 mg once daily, and higher doses are not recommended except with efavirenz (atazanavir SmPC, EMA, sections 4.2 and 4.4). Atazanavir is used with special precautions with drugs that can prolong the QT interval (atazanavir SmPC, EMA, section 4.4). Before and during voriconazole treatment, potassium, magnesium and calcium are monitored and corrected if needed (voriconazole SmPC, EMA, section 4.4).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Vfend (voriconazole) prescribing information – CYP3A4 inhibitor, statin/immunosuppressant interactions (2020)– FDA Vfend label, Drug Interactions §7 – tacrolimus, cyclosporine, sirolimus, statins; DailyMed setid ce3ef5cf-3087-4d92-9d94-9eb8287228db
- FDA: Reyataz (atazanavir) prescribing information (2024)– DailyMed setid 165cff62-b284-4a27-a65d-9ec8a5bfcdd8, revisión 12/2024, secciones 4 y 7.3
- EMA: Ficha técnica: Voriconazol, Vfend (EU/1/02/212), secciones 4.3, 4.4 y 4.5 (2026)– EMA, SmPC Vfend 200 mg comprimidos, EU/1/02/212, texto en CIMA nº registro 02212015, consultado 11.10.2026, sin fecha de revisión en CIMA, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Atazanavir/cobicistat (EU/1/15/1025), sección 4.5 (2026)– EMA, Evotaz 300 mg/150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151025001, consultada 10/2026, secciones 4.3 y 4.5
- EMA: Ficha técnica: Atazanavir, Reyataz (EU/1/03/267), sección 4.3 (2026)– EMA, Reyataz 300 mg cápsulas (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 03267008, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.2, 4.3, 4.4 y 4.5